secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001213900-24-095506
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma enters employment agreement with CEO Cheng Liu; base salary $250,000
--------------------------------------------------------------------------------

- Base salary of $250,000 per year, plus annual cash bonus based on performance metrics set by Compensation Committee.
- Severance: 6 months base salary for termination without cause or resignation for good reason; 12 months plus equity acceleration if tied to change in control.
- Agreement includes non-disclosure and confidentiality covenants; effective November 1, 2024, at-will employment.
- CEO retains ability to hold outside directorships and positions, subject to Board review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024095506/0001213900-24-095506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024095506/ea0220428-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-095506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer